RA Capital Management 13F holdings, Q2 2024
Holdings as of June 30, 2024 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 78 US equity positions worth $7.7bn in its Q2 2024 13F filing. The largest position was ASND at 17.8% of the reported book, followed by PCVX and CLYM. Against the Q1 2024 filing, it opened 3 new positions, added to 20 and reduced 2 among the top 50 holdings.
What did RA Capital Management own in Q2 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 17.8% | $1.4bn | 10,108,400 | 0% | held |
| 2 | PCVX VAXCYTE INC | Healthcare | 8.0% | $619.5m | 8,203,754 | 0% | held |
| 3 | CLYM ELIEM THERAPEUTICS INC | 5.3% | $411.5m | 31,419,267 | 139% | added | |
| 4 | JANX JANUX THERAPEUTICS INC | Healthcare | 5.0% | $383.9m | 9,165,652 | 0% | held |
| 5 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 4.3% | $332.5m | 7,506,934 | 9% | added |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.2% | $249.8m | 6,084,412 | 14% | added |
| 7 | BIIB BIOGEN INC | Healthcare | 2.9% | $227.7m | 982,139 | 33% | added |
| 8 | RXST RXSIGHT INC | Healthcare | 2.9% | $222.3m | 3,694,825 | 7% | added |
| 9 | AVIDITY BIOSCIENCES INC | 2.8% | $220.6m | 5,400,408 | 65% | added | |
| 10 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.8% | $213.5m | 6,049,204 | 22% | added |
| 11 | GERN GERON CORP | Healthcare | 2.5% | $195.9m | 46,202,425 | 0% | held |
| 12 | PEPG PEPGEN INC | Healthcare | 2.2% | $170.6m | 10,689,545 | 0% | held |
| 13 | TYRA TYRA BIOSCIENCES INC | Healthcare | 2.1% | $166.6m | 10,416,609 | 0% | held |
| 14 | EVH EVOLENT HEALTH INC - A | Healthcare | 2.1% | $162.8m | 8,514,862 | 48% | added |
| 15 | EWTX EDGEWISE THERAPEUTICS INC | 2.1% | $160.5m | 8,909,091 | 0% | held | |
| 16 | NEWAMSTERDAM PHARMA CO NV | 2.0% | $154.9m | 8,064,000 | 3% | added | |
| 17 | RXRX RECURSION PHARMACEUTICALS-A | Healthcare | 1.5% | $115.4m | 15,384,615 | – | new |
| 18 | 89BIO INC | 1.5% | $113.5m | 14,175,398 | 11% | added | |
| 19 | VRNA VERONA PHARMA PLC - ADR | 1.4% | $110.4m | 7,632,646 | 21% | added | |
| 20 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.4% | $108.5m | 7,871,721 | 1% | added | |
| 21 | 4D MOLECULAR THERAPEUTICS IN | 1.4% | $107.0m | 5,098,211 | 1% | added | |
| 22 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 1.2% | $92.4m | 10,860,977 | 0% | held |
| 23 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.2% | $90.8m | 18,202,009 | 0% | held |
| 24 | LONGBOARD PHARMACEUTICALS IN | 1.1% | $88.9m | 3,289,119 | 0% | held | |
| 25 | ARCELLX INC | 1.1% | $88.5m | 1,604,014 | – | new | |
| 26 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.0% | $80.5m | 1,000,000 | 0% | held |
| 27 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.0% | $77.2m | 1,961,863 | -1% | reduced |
| 28 | GHRS GH RESEARCH PLC | 1.0% | $77.0m | 6,601,689 | 6% | added | |
| 29 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.0% | $74.5m | 1,896,772 | 26% | added |
| 30 | LENZ LENZ THERAPEUTICS INC | Healthcare | 0.9% | $72.3m | 4,178,823 | 0% | held |
| 31 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.9% | $72.0m | 11,609,704 | 0% | held |
| 32 | NKTX NKARTA INC | Healthcare | 0.8% | $63.9m | 10,805,129 | 0% | held |
| 33 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.8% | $60.4m | 2,333,000 | 0% | held |
| 34 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.7% | $56.8m | 4,850,984 | 0% | held |
| 35 | ITEOS THERAPEUTICS INC | 0.7% | $52.2m | 3,517,259 | -20% | reduced | |
| 36 | URGN UROGEN PHARMA LTD | Healthcare | 0.7% | $51.7m | 3,083,430 | 0% | held |
| 37 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.7% | $51.1m | 1,235,599 | 49% | added |
| 38 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.6% | $49.6m | 2,122,465 | 0% | held |
| 39 | ACRV ACRIVON THERAPEUTICS INC | 0.6% | $48.4m | 8,340,508 | 73% | added | |
| 40 | ASTRIA THERAPEUTICS INC | 0.6% | $45.9m | 5,043,756 | 14% | added | |
| 41 | BCYC BICYCLE THERAPEUTICS PLC-ADR | Healthcare | 0.6% | $45.6m | 2,253,000 | 182% | added |
| 42 | CGON CG ONCOLOGY INC | Healthcare | 0.6% | $44.1m | 1,397,433 | 0% | held |
| 43 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.6% | $43.8m | 6,045,351 | 0% | held |
| 44 | ABOS ACUMEN PHARMACEUTICALS INC | 0.5% | $36.1m | 14,932,063 | 0% | held | |
| 45 | TOURMALINE BIO INC | 0.4% | $32.7m | 2,538,925 | – | new | |
| 46 | THIRD HARMONIC BIO INC | 0.3% | $26.4m | 2,033,056 | 0% | held | |
| 47 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.3% | $24.6m | 4,330,446 | 0% | held |
| 48 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.3% | $24.4m | 10,872,503 | 0% | held |
| 49 | TNYA TENAYA THERAPEUTICS INC | 0.3% | $23.6m | 7,622,347 | 32% | added | |
| 50 | VOR VOR BIOPHARMA INC | 0.3% | $22.7m | 22,748,880 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.